CliffBio
small molecule

OSPHENA

OSPEMIFENE

Loss of exclusivityJuly 2028latest FDA-listed patent expiry
CompanyDuchesnay Usa →See this company's full patent-cliff portfolio

Drug detail

Brand nameOSPHENA
Active ingredientOSPEMIFENE
Strength60MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2013
Marketing statusRX

Listed patents

PatentExpiresType
8642079July 2028product
8236861August 2026use U-1370

More from Duchesnay Usa

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OSPHENA patent cliff — loss of exclusivity July 2028 | CliffBio